Flumequine Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:449624549
Iupac Name:7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.0<sup>5,13</sup>]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
Legal Status:withdrawn
Excretion:urine and feces
Cas Number:42835-25-6
Atc Prefix:J01
Atc Suffix:MB07
Pubchem:3374
Drugbank:DB08972
Chebi:85267
Unii:UVG8VSP2SJ
Kegg:D02302
Chemspiderid:3257
Smiles:Fc2cc1C(=O)/C(C(=O)O)=C\N3c1c(c2)CCC3C
Stdinchi:1S/C14H12FNO3/c1-7-2-3-8-4-9(15)5-10-12(8)16(7)6-11(13(10)17)14(18)19/h4-7H,2-3H2,1H3,(H,18,19)
Stdinchikey:DPSPPJIUMHPXMA-UHFFFAOYSA-N
C:14
H:12
F:1
N:1
O:3
Synonyms:9-Fluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[''ij'']-quinolizine-2-carboxylic acid
Melting Point:253
Melting High:255

Flumequine[1] is a synthetic fluoroquinolone antibiotic[2] [3] used to treat bacterial infections. It is a first-generation fluoroquinolone antibacterial that has been removed from clinical use and is no longer being marketed.[4] The marketing authorization of flumequine has been suspended throughout the EU.[5] It kills bacteria by interfering with the enzymes that cause DNA to unwind and duplicate. Flumequine was used in veterinarian medicine for the treatment of enteric infections (all infections of the intestinal tract),[6] as well as to treat cattle, swine, chickens, and fish, but only in a limited number of countries.[4] [7] [8] It was occasionally used in France (and a few other European Countries) to treat urinary tract infections under the trade name Apurone.[4] [9] However this was a limited indication[10] because only minimal serum levels were achieved.[11]

History

The first quinolone used was nalidixic acid (was marketed in many countries as Negram) followed by the fluoroquinolone flumequine.[4] The first-generation fluoroquinolone agents, such as flumequine, had poor distribution into the body tissues and limited activity. As such they were used mainly for treatment of urinary tract infections. Flumequine (benzo quinolizine) was first patented in 1973, (German Patent) by Rikker Labs.[12] Flumequine is a known antimicrobial compound described and claimed in U.S. Pat. No. 3,896,131 (Example 3), July 22, 1975.[13] Flumequine is the first quinolone compound with a fluorine atom at the C6-position of the related quinolone basic molecular structure.[14] Even though this was the first fluoroquinolone, it is often overlooked when classifying the drugs within this class by generations and excluded from such a list.

Though used frequently to treat farm animals and on occasion household pets, flumequine was also used to treat urinary tract infections in humans. Flumequine, was used transiently treat urinary infections[9] until ocular toxicity was reported.[15] [16] [17] as well as liver damage[18] and anaphylactic shock.[19] [20]

In 2008, the United States Food and Drug Administration (FDA) requested that all quinolone/fluoroquinolone drugs package inserts include a Black Boxed Warning concerning the risk of spontaneous tendon ruptures, which would have included flumequine. The FDA also requested that the manufacturers send out Dear Doctor Letters regarding this new warning. Such tendon problems have also been associated with flumequine.[21]

Drug residue

The use of flumequine in food animals had sparked considerable debate. Significant and harmful residues of quinolones have been found in animals treated with quinolones and later slaughtered and sold as food products. There has been significant concern regarding the amount of flumequine residue found within food animals such as fish, poultry and cattle.[22] [23] In 2003 the Joint FAO/WHO Committee on Food Additives (JECFA) withdrew the maximum residue limits (MRLs) for flumequine and carbadox based on evidence showing both are direct acting genotoxic carcinogens, therefore the Committee was unable to establish an Acceptable Daily Intake (ADI) for human exposure to such residues.[24] Subsequently, in 2006, the JEFCA, re-established the ADI having received appropriate evidence and MRLs were re-specified. The role of JECFA is to evaluate toxicology, residue chemistry and related information and make recommendations for acceptable daily intake (ADI) levels and maximum residue limits (MRLs). At its 16th session, held May 2006, the Committee on Residues of Veterinary Drugs in Foods (CCRVDF) requested information on registered uses of flumequine. As the CCRVDF did not receive any information regarding the registered uses of flumequine that they had requested, the committee members agreed to discontinue work on the MRLs for flumequine in shrimp.[25] [26]

Licensed uses

Urinary tract infections (veterinary and human)[27]

Availability

Veterinary use:

Human use:

Mode of action

Flumequine is a member of the quinolone antibiotics family, which are active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV,[28] enzymes necessary to separate bacterial DNA, thereby inhibiting cell division.

This mechanism can also affect mammalian cell replication. In particular, some congeners of this drug family (for example those that contain the C-8 fluorine),[29] display high activity not only against bacterial topoisomerases, but also against eukaryotic topoisomerases and are toxic to cultured mammalian cells and in vivo tumor models.[30]

Although quinolones are highly toxic to mammalian cells in culture, its mechanism of cytotoxic action is not known. Quinolone induced DNA damage was first reported in 1986 (Hussy et al.).[31]

Recent studies have demonstrated a correlation between mammalian cell cytotoxicity of the quinolones and the induction of micronuclei.[32] [33] [34] [35]

As such, some fluoroquinolones may cause injury to the chromosome of eukaryotic cells.[36] [37] [38] [39] [40] [41]

There continues to be considerable debate as to whether or not this DNA damage is to be considered one of the mechanisms of action concerning the severe adverse reactions experienced by some patients following fluoroquinolone therapy.[30] [42]

Adverse reactions

Flumequine was associated with severe ocular toxicity, which precluded its use in human patients.[15] [16] [17] Drug-induced calculi (kidney stones) has been associated with such therapy as well.[43] [44] [45] Anaphylactic shock induced by flumequine therapy has also been associated with its use.[19] [20] [46] Anaphylactoid reactions such as shock, urticaria, and Quincke’s oedema have been reported to generally appear within two hours after taking the first tablet. There were eighteen reports listed within the WHO file in 1996.[47] As with all drugs within this class, flumequine therapy may result in severe central nervous system (CNS) reactions,[48] [49] [50] phototoxicity resulting in skin reactions like erythema, pruritus, urticaria and severe rashes,[51] [52] gastrointestinal and neurological disorders.[9]

Drug interactions

Flumequine was found to have no effect on theophylline pharmacokinetics.[53]

Chemistry

Flumequine is a 9-fluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid. The molecular formula is C14H12FNO3. It is a white powder, odorless, flavorless, insoluble in water but soluble in organic solvent.[54]

Pharmacokinetics

Flumequine is considered to be well absorbed and is excreted in the urine and feces as the glucuronide conjugates of the parent drug and 7-hydroxyflumequine. It is eliminated within 168 hours post-dosing. However, studies concerning the calf liver showed additional unidentified residues, of which a new metabolite, ml, represented the major single metabolite 24 hours after the last dose and at all subsequent time points. The metabolite ml, which exhibited no antimicrobial activity, was present in both free and protein-bound fractions. The major residue found in the edible tissues of sheep, pigs, and chickens was parent drug together with minor amounts of the 7-hydroxy-metabolite. The only detected residue in trout was the parent drug.[55]

See also

Notes and References

  1. INN: Lomefloxacin Hydrochloride
  2. Nelson JM, Chiller TM, Powers JH, Angulo FJ . Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story . Clinical Infectious Diseases . 44 . 7 . 977–980 . April 2007 . 17342653 . 10.1086/512369 . free .
  3. Kawahara S . [Chemotherapeutic agents under study] . ja . Nihon Rinsho. Japanese Journal of Clinical Medicine . 56 . 12 . 3096–3099 . December 1998 . 9883617 .
  4. Web site: Quinolones and fluoroquinolones . Pharmacorama . 2010-04-04 . 2019-05-12 . https://web.archive.org/web/20190512062422/https://www.pharmacorama.com/en/Sections/Nucleic-acids-7.php . dead .
  5. Web site: Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. 11 March 2019. European Medicines Agency.
  6. Book: Francis PG, Wells RJ . 1998 . Flumequine . Joint FAO/WHO Expert Committee on Food Additives. Residues of some veterinary drugs in animals and foods. . Rome . Food and Agriculture Organization . 92-5-104128-8 . 39798999 .
  7. Use of quinolones in food animals and potential impact on human health . WHO meeting . Geneva, Switzerland . June 1998 . World Health Organization . https://web.archive.org/web/20100114022417/https://www.fda.gov/ohrms/dockets/dailys/03/Aug03/081403/03n-0324-bkg0001-10-tab7-vol2.pdf . 14 January 2010 . Cattle only in Europe and Latin America. (Limited use in Latin America), Poultry only in Europe, Asia and Latin America, Fish only in Asia
  8. Web site: Lavenberg DL . Bayer . U.S. Food and Drug Administration . IX4Q 4586, Brrytrit 3.23% Concentrate Solution for Use in Chicken Drinking Water, Genera. Correspondence, Published Literure . Quinalones are often used to treat severe cases of human infection with Campylobacter spp., and they are also used in veterinary medicine, especially for treating poultry. . https://web.archive.org/web/20121005062843/https://www.fda.gov/ohrms/dockets/dailys/02/Jan02/011102/00n-1571_c000191_06_Exhibit_05_vol25.pdf . 5 October 2012 .
  9. Schena FP, Gesualdo L, Caracciolo G . A multicentre study of flumequine in the treatment of urinary tract infections . The Journal of Antimicrobial Chemotherapy . 21 . 1 . 101–106 . January 1988 . 3356617 . 10.1093/jac/21.1.101 .
  10. The quinolones (Third Edition 2000)By Vincent T. Andriole Chapter I History and overview By Dr. Peter Ball(page 5)
  11. King DE, Malone R, Lilley SH . New classification and update on the quinolone antibiotics . American Family Physician . 61 . 9 . 2741–2748 . May 2000 . 10821154 .
  12. 10.1093/rpc/rcn037 . Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd . 2009 . Reports of Patent, Design and Trade Mark Cases . 126 . 102 . 2. free .
  13. Web site: Substituted benzo(ij)quinolizine-2-carboxylic acids and derivatives thereof - Patent 3896131 . Freepatentsonline.com . 2010-04-04.
  14. Takahashi H, Hayakawa I, Akimoto T . [The history of the development and changes of quinolone antibacterial agents] . ja . Yakushigaku Zasshi . 38 . 2 . 161–179 . 2003 . 15143768 .
  15. Sirbat D, Saudax E, Hurault de Ligny B, Hachet E, Abellan P, George JL . [Serous macular detachment and treatment with flumequine (Apurone = urinary antibacterial). Apropos of 2 cases] . fr . Bulletin des Sociétés d'Ophtalmologie de France . 83 . 8–9 . 1019–1021 . 1983 . 6378414 .
  16. Hurault de Ligny B, Sirbat D, Kessler M, Trechot P, Chanliau J . [Ocular side effects of flumequine. 3 cases of macular involvement] . fr . Therapie . 39 . 5 . 595–600 . 1984 . 6506018 .
  17. Ball P . Quinolone generations: natural history or natural selection? . The Journal of Antimicrobial Chemotherapy . 46 . Suppl T1 . 17–24 . July 2000 . 10997595 . 10.1093/oxfordjournals.jac.a020889 . free .
  18. Dubois A, Janbon C, Pignodel C, Marty-Double C . [Immunoallergic hepatitis induced by flumequine] . fr . Gastroenterologie Clinique et Biologique . 7 . 2 . 217–218 . February 1983 . 6840466 .
  19. Pinzani V, Gennaro G, Petit P, Blayac JP . [Anaphylactic shock induced by flumequine] . fr . Therapie . 47 . 5 . 440 . 1992 . 1299991 .
  20. Marsepoil T, Blin F, Lo JM, Horel D'Ancona F, Sebbah JL . [A case of anaphylactic shock induced by flumequine] . fr . Presse Médicale . 14 . 32 . 1712 . September 1985 . 2932732 .
  21. Web site: Fluoroquinolones- A Review– Dr.T R RAMANUJAM.M.D . Medindia.net . 2010-04-04.
  22. Karbiwnyk CM, Hibbard LE, Lee RH . Confirmation of Oxolinic Acid and Flumequine Residues in Shrimp by Liquid Chromatography with Tandem Mass Spectrometry Detection . April 27–28, 2005 . FDA Science. etal.
  23. Web site: Chemotherapeutics in Seafood Compliance Program: Chapter 4: Pesticides and Chemical Contaminants . 7304.018 . U.S. Food and Drug Administration . Compliance Program Guidance Manual . Residue found in Catfish/Basa, Shrimp, salmon, trout . https://web.archive.org/web/20110307104219/https://www.fda.gov/downloads/Food/GuidanceComplianceRegulatoryInformation/ComplianceEnforcement/ucm073192.pdf . 7 March 2011 .
  24. Web site: FAO/WHO Expert Committee on Food Additives, Geneva, Switzerland . Fda.gov . 2009-10-28 . 2010-04-04.
  25. Web site: FDA Veterinarian Newsletter, Volume XXII, No. V, 2007 . . 2010-04-04.
  26. Web site: Codex Committee on Veterinary Drug Residues Acts on Several Documents at 17th Session . Fda.gov . 2009-10-28 . 2010-04-04.
  27. WHO Drug Information Vol. 2, No. 3, 1988
  28. Drlica K, Zhao X . DNA gyrase, topoisomerase IV, and the 4-quinolones . Microbiology and Molecular Biology Reviews . 61 . 3 . 377–392 . September 1997 . 9293187 . 232616 . 10.1128/mmbr.61.3.377-392.1997 .
  29. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N . Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group . Antimicrobial Agents and Chemotherapy . 36 . 4 . 751–756 . April 1992 . 1323952 . 189387 . 10.1128/aac.36.4.751 .
  30. Sissi C, Palumbo M . The quinolone family: from antibacterial to anticancer agents . Current Medicinal Chemistry. Anti-Cancer Agents . 3 . 6 . 439–450 . November 2003 . 14529452 . 10.2174/1568011033482279 . The present review focuses on the structural modifications responsible for the transformation of an antibacterial into an anticancer agent. Indeed, a distinctive feature of drugs based on the quinolone structure is their remarkable ability to target different type II topoisomerase enzymes. In particular, some congeners of this drug family display high activity not only against bacterial topoisomerases but also against eukaryotic topoisomerases and are toxic to cultured mammalian cells and in vivo tumor models .
  31. Hussy P, Maass G, Tümmler B, Grosse F, Schomburg U . Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts . Antimicrobial Agents and Chemotherapy . 29 . 6 . 1073–1078 . June 1986 . 3015015 . 180502 . 10.1128/AAC.29.6.1073 .
  32. Hosomi J, Maeda A, Oomori Y, Irikura T, Yokota T . 1988 . Mutagenicity of Norfloxacin and AM-833 in Bacteria and Mammalian Cells . Reviews of Infectious Diseases . 10 . Supplement 1 . S148–9 . 4454399.
  33. Forsgren A, Bredberg A, Pardee AB, Schlossman SF, Tedder TF . Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth . Antimicrobial Agents and Chemotherapy . 31 . 5 . 774–779 . May 1987 . 3606077 . 174831 . 10.1128/AAC.31.5.774 .
  34. Gootz TD, Barrett JF, Sutcliffe JA . Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems . Antimicrobial Agents and Chemotherapy . 34 . 1 . 8–12 . January 1990 . 2158274 . 171510 . 10.1128/AAC.34.1.8 .
  35. Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, Rowe TC . 4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells . Journal of Cellular Biochemistry . 51 . 2 . 165–174 . February 1993 . 8440750 . 10.1002/jcb.240510208 . 41291987 .
  36. Elsea SH, Osheroff N, Nitiss JL . Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast . The Journal of Biological Chemistry . 267 . 19 . 13150–13153 . July 1992 . 1320012 . 10.1016/S0021-9258(18)42185-0 . free .
  37. Suto MJ, Domagala JM, Roland GE, Mailloux GB, Cohen MA . Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity . Journal of Medicinal Chemistry . 35 . 25 . 4745–4750 . December 1992 . 1469702 . 10.1021/jm00103a013 .
  38. Enzmann H, Wiemann C, Ahr HJ, Schlüter G . Damage to mitochondrial DNA induced by the quinolone Bay y 3118 in embryonic turkey liver . Mutation Research . 425 . 2 . 213–224 . April 1999 . 10216214 . 10.1016/S0027-5107(99)00044-5 .
  39. Kashida Y, Sasaki YF, Ohsawa K, Yokohama N, Takahashi A, Watanabe T, Mitsumori K . Mechanistic study on flumequine hepatocarcinogenicity focusing on DNA damage in mice . Toxicological Sciences . 69 . 2 . 317–321 . October 2002 . 12377980 . 10.1093/toxsci/69.2.317 . free .
  40. Thomas A, Tocher J, Edwards DI . Electrochemical characteristics of five quinolone drugs and their effect on DNA damage and repair in Escherichia coli . The Journal of Antimicrobial Chemotherapy . 25 . 5 . 733–744 . May 1990 . 2165050 . 10.1093/jac/25.5.733 .
  41. Web site: Fluoroquinolones and Quinolones. 29 January 2009. The American Academy of Optometry (British Chapter) .
  42. 10.1590/S0103-50532003000500014 . A new class of dihaloquinolones bearing N'-aldehydoglycosylhydrazides, mercapto-1,2,4-triazole, oxadiazoline and a-amino ester precursors: synthesis and antimicrobial activity . 2003 . Al-Soud YA, Al-Masoudi NA . Journal of the Brazilian Chemical Society . 14 . 5 . 790–796. free .
  43. Daudon M, Protat MF, Réveillaud RJ . [Detection and diagnosis of drug induced lithiasis] . fr . Annales de Biologie Clinique . 41 . 4 . 239–249 . 1983 . 6139048 .
  44. Rincé C, Daudon M, Moesch C, Rincé M, Leroux-Robert C . Identification of flumequine in a urinary calculus . Journal of Clinical Chemistry and Clinical Biochemistry . 25 . 5 . 313–314 . May 1987 . 3612030 .
  45. Reveillaud RJ, Daudon M . [Drug-induced urinary lithiasis] . fr . Presse Médicale . 12 . 38 . 2389–2392 . October 1983 . 6138768 .
  46. Arboit F, Bessot JC, DeBlay F, Dietemann A, Charpentier C, Pauli G . Eight cases of quinolone allergy. . Revue Française d'Allergologie et d'Immunologie Clinique . January 1997 . 37 . 1 . 15–19 . 10.1016/S0335-7457(97)80204-3 .
  47. http://www.who-umc.org/graphics/10575.pdf Adverse Reaction Newsletter 1996:1
  48. Christ W . Central nervous system toxicity of quinolones: human and animal findings . The Journal of Antimicrobial Chemotherapy . 26 . Suppl B . 219–225 . October 1990 . 2124211 . 10.1093/jac/26.suppl_b.219 .
  49. Defoin JF, Debonne T, Rambourg MO, Seraphin J, Buffet M, Jaussaud M, Bertault R, Fay R, Digeon B . 6 . [Acute psychiatric syndrome and quinolones] . fr . Journal de Toxicologie Clinique et Expérimentale . 10 . 7–8 . 469–472 . 1990 . 2135062 .
  50. Rampa S, Caroli F . [Neuropsychiatric manifestations and quinolones. Apropos of a case] . fr . L'Encephale . 17 . 6 . 511–514 . 1991 . 1666873 .
  51. Vermeersch G, Filali A, Marko J, Catteau JP, Couture A . [Photophysical evaluation of photosensitization by various quinolones] . fr . Journal de Pharmacie de Belgique . 45 . 5 . 299–305 . 1990 . 1964964 .
  52. Revuz J, Pouget F . [Photo-onycholysis caused by Apurone] . fr . Annales de Dermatologie et de Venereologie . 110 . 9 . 765 . 1983 . 6660786 .
  53. Lacarelle B, Blin O, Audebert C, Auquier P, Karsenty H, Horriere F, Durand A . The quinolone, flumequine, has no effect on theophylline pharmacokinetics . European Journal of Clinical Pharmacology . 46 . 5 . 477–478 . 1994 . 7957547 . 10.1007/bf00191915 . 97621 .
  54. Web site: Flumequine(antiniotic antimicrobial agents) Manufacturers & Suppliers . 88chem.com . 2010-04-04.
  55. Web site: Flumequine . Francis PG, Wells RJ . Australian Government Analytical Laboratories . Pymble, Australia .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Flumequine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.